Pulmonary arterial hypertension among Filipino patients with connective tissue diseases

Modern Rheumatology

Volumn 17, Issue 3, 2007, Pages 224-227

  Santos Estrella, Paul V ^a,b   Lin, Yih Chang ^a,b   Navarra, Sandra V ^a,b  

^a ST LUKE S MEDICAL CENTER   (Philippines)

^b UNIVERSITY OF SANTO TOMAS   (Philippines)

Author keywords

Connective tissue diseases; Filipino; Pulmonary hypertension

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; SILDENAFIL; STEROID; WARFARIN;

ADULT; AGE DISTRIBUTION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; DISEASE DURATION; DRUG RESPONSE; EARLY DIAGNOSIS; FEMALE; FILIPINO; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PHILIPPINES; RETROSPECTIVE STUDIES;

EID: 34250643167     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0569-8     Document Type: Review

References (29)

1. BW Christman CD McPherson JH Newman GA King GR Bernard BM Groves JE Loyd 1992 An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 2 70-5 1603138 1:STN:280:By2B1MzislY%3D
2. A Giaid M Yanagisawa D Langleben RP Michel R Levy H Shennib 1993 Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 24 1732-9 8497283 10.1056/ NEJM199306173282402 1:STN:280:ByyB28fjsVY%3D
3. A Giaid D Saleh 1995 Reduced expression of endothelial nitric oxide synthase in the lungs of patient with pulmonary hypertension N Engl J Med 333 214-21 7540722 10.1056/NEJM199507273330403 1:STN:280:ByqA3M3gtlA%3D
4. Rich S, editor. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6-10, 1998, co-sponsored by the World Health Organization; 1998
5. DB Badesch SH Abman GS Ahearn RJ Barst DC McCrory G Simonneau 2004 Medical therapy for pulmonary arterial hypertension Chest 126 35S-62S 15249494 10.1378/chest.126.1_suppl.35S
6. MM Hoeper 2002 Pulmonary hypertension in collagen vascular disease Eur Respir J 19 571-6 11936539 10.1183/09031936.02.01512001 1:STN:280:DC%2BD383gtlahuw%3D%3D
7. MC Lim SV Navarra MY Tan-Ong 2002 Clinical presentation and disease course of pulmonary hypertension among Filipinos with systemic lupus erythematosus Philipp J Intern Med 40 140-3
8. Klippel JH, Crofford LJ, Stone JH, Weyand CM. Primer on the rheumatic diseases. 12th ed. Arthritis Foundation, Atlanta, Georgia 2001
9. G Simmoneau N Galie LJ Rubin D Langleben W Seeger G Domenighetti 2004 Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 Suppl 12 5S-12S 10.1016/j.jacc.2004.02.037
10. Harris EN, Khamashta MA. Antiphospholipid syndrome. Rheumatology. 3rd ed. Mosby 2003
11. JS Levine 2002 The antiphospholipid syndrome N Engl J Med 346 10 752-63 11882732 10.1056/NEJMra002974 1:CAS:528:DC%2BD38XhslOnsb8%3D
12. ET Koh P Lee DD Gladman M Abu-Shakra 1996 Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients Br J Rheumatol 35 989-93 8883438 10.1093/rheumatology/35.10.989 1:STN:280:ByiD3sjotFQ%3D
13. G Rolla P Colagrande E Scappaticci G Chiavassa L Dutto S Cannizzo 2000 Exhaled nitric oxide in systemic sclerosis: Relationships with lung involvement and pulmonary hypertension J Rheumatol 27 1693-8 10914853 1:CAS:528:DC%2BD3cXltlKqsLs%3D
14. RW Battle MA Davitt SM Cooper LM Buckley ES Leib PA Beglin 1996 Prevalence of pulmonary hypertension in limited and diffuse scleroderma Chest 110 1515-9 8989070 1:STN:280:ByiC2czgsF0%3D
15. I Murata H Kihara S Shinohara K Ito 1992 Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes Jpn Circ J 56 983-91 1433824 1:STN:280:ByyD28%2Fgs1I%3D
16. K Yamane H Ihn Y Asano N Yazawa M Kubo K Kikuchi 2000 Clinical and laboratory features of scleroderma patients with pulmonary hypertension Rheumatology (Oxford) 39 1269-71 10.1093/rheumatology/39.11.1269 1:STN:280:DC%2BD3M%2FmtlKiuw%3D%3D
17. MA Burdt RW Hoffman SL Deutscher GS Wang JC Johnson GC Sharp 1999 Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings Arthritis Rheum 42 899-909 10323445 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L 1:STN:280:DyaK1M3lsFShtg%3D%3D
18. AL Hinderliter PW Willis IV RJ Barst S Rich LJ Rubin DB Badesch 1997 Effects of long term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary pulmonary hypertension study group Circulation 95 1479-86 9118516 1:CAS:528:DyaK2sXisVakuro%3D
19. JY Shen SL Chen YX Wu RQ Tao YY Gu CD Bao 1999 Pulmonary hypertension in systemic lupus erythematosus Rheumatol Int 18 147-51 10220835 10.1007/ s002960050074 1:STN:280:DyaK1M3jslWrtg%3D%3D
20. TM Winslow MA Ossipov GP Fazio E Foster JS Simonson NB Schiller 1993 The left ventricle in systemic lupus erythematosus: Initial observation and a five-year follow-up in a university medical center population Am Heart J 125 1117-22 8465737 10.1016/0002-8703(93)90123-Q 1:STN:280:ByyB38%2FlvVA%3D
21. E Tanaka M Harigai M Tanaka Y Kawaguchi M Hara N Kamatani 2002 Pulmonary hypertension in systemic lupus erythematosus: Evaluation of clinical characteristics and response to immunosuppressive treatment J Rheumatol 29 282-7 11838845
22. TA Medsger PH Shur 1996 The clinical management of systemic lupus erythematosus 2nd ed Lippincott-Raven New York 89
23. DJ Wallace HB Hahn 1997 Dubois' lupus erythematosis 5th ed Williams and Wilkins Maryland 682-4
24. M McGoon D Gutterman V Steen R Barst DC McCrory TA Fortin 2004 Screening, early detection, and diagnosis of pulmonary arterial hypertension Chest 126 Suppl 14S-34S 10.1378/chest.126.1_suppl.14S
25. DC McCrory 2004 Methodology and grading for pulmonary hypertension evidence review and guideline development Chest 126 11S-13S 15249492 10.1378/chest.126.1_suppl.11S
26. BW Christman CD McPherson JH Newman GA King GR Bernard BM Groves 1992 An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 70-5 1603138 1:STN:280:By2B1MzislY%3D
27. RM Tuder CD Cool MW Geraci J Wang SH Abman L Wright 1999 Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 1925-32 10351941 1:STN:280:DyaK1M3otVKmsQ%3D%3D
28. MR MacLean 1998 Endothelin-1: A mediator of pulmonary hypertension? Pulm Pharmacol Ther 11 125-32 9918744 10.1006/pupt.1998.0126 1:CAS:528:DyaK1MXpsVOjtg%3D%3D
29. A Benigni G Remuzzi 1999 Endothelin antagonists Lancet 353 133-8 10023915 10.1016/S0140-6736(98)09423-9 1:CAS:528:DyaK1MXms1Gnug%3D%3D